Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine

Antimicrob Agents Chemother. 2002 May;46(5):1586-8. doi: 10.1128/AAC.46.5.1586-1588.2002.

Abstract

Adefovir dipivoxil (ADV) at a suboptimal concentration for human immunodeficiency virus type 1 (HIV-1) (10 mg once daily) can be used to treat hepatitis B virus (HBV) infection in HIV-1-HBV-coinfected patients and does not, even in the case of uncontrolled HIV-1 replication, select for either ADV mutations at codons 65 and 70 or any other particular HIV-1 reverse transcriptase resistance profile.

MeSH terms

  • Adenine / administration & dosage
  • Adenine / analogs & derivatives*
  • Adenine / therapeutic use*
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use
  • Drug Resistance, Viral / genetics*
  • Drug Therapy, Combination
  • HIV Infections / complications
  • HIV Infections / drug therapy
  • HIV Reverse Transcriptase / drug effects
  • HIV Reverse Transcriptase / genetics*
  • HIV-1 / drug effects
  • HIV-1 / enzymology
  • HIV-1 / genetics
  • Hepatitis B virus / drug effects
  • Hepatitis B, Chronic / complications*
  • Hepatitis B, Chronic / drug therapy
  • Humans
  • Lamivudine / administration & dosage
  • Lamivudine / therapeutic use*
  • Mutation
  • Organophosphonates*
  • Reverse Transcriptase Inhibitors / administration & dosage
  • Reverse Transcriptase Inhibitors / therapeutic use*

Substances

  • Antiviral Agents
  • Organophosphonates
  • Reverse Transcriptase Inhibitors
  • Lamivudine
  • HIV Reverse Transcriptase
  • Adenine
  • adefovir dipivoxil